Rick Doblin (born November 30, 1953) is the president and founder of the Multidisciplinary Association for Psychedelic Studies (MAPS).
|Born||November 30, 1953|
|Alma mater||New College of Florida
Harvard's John F. Kennedy School of Government
|Occupation||Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)|
|Known for||Psychedelic therapy, MAPS|
Career and education
He co-founded Earth Metabolic Design Laboratories in 1984 to support psychedelic research and Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986 with the goal of making MDMA (or Ecstasy) an FDA-approved medicine. He subsequently obtained a psychology degree from New College of Florida in 1987 and earned a doctorate in public policy from the Kennedy School of Government, Harvard University in 2001.
In the early 1980s, Doblin owned and operated a company called Abraxas Construction, located in the Sarasota, Florida area, which specialized in relocating houses.
- Frith, C.; Chang, L.; Lattin, D.; Walls, R.; Hamm, J.; Doblin, R. (1987). "Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat". Fundamental and Applied Toxicology 9 (1): 110–19.
- Doblin, R. (1991). "Pahnke's "Good Friday Experiment": A long-term follow-up and methodological critique". Journal of Transpersonal Psychology 23 (1): 1–28.
- Doblin, R.; Kleiman, M. (May 1, 1991). "Medical use of marijuana". Annals of Internal Medicine 114 (9): 809–10.
- Doblin, R.; Kleiman, M. (July 1991). "Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes.". Journal of Clinical Oncology 9 (7): 1314–1319. PMID 2045870.
- Grinspoon, L.; Bakalar, J.; Doblin, R. (1995). "Marijuana, the AIDS wasting syndrome, and the U.S. government". The New England Journal of Medicine 333 (10): 670–1.
- Doblin, R.; Kleiman, M. (1995). "The medical use of marijuana: the case for clinical trials". Journal of Addictive Diseases 14 (1): 5–14.
- Doblin, R.; Kleiman, M. (1998). "Survey research vs clinical trials in evaluating the medical utility of marijuana". Southern Medical Journal 91 (10): 989–91.
- Doblin, R. (1998). "Dr. Leary's Concord Prison Experiment". Journal of Psychoactive Drugs 30 (4): 419–426.
- Regulation of the Medical Use of Psychedelics and Marijuana . A dissertation by R. Doblin for his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. June 2002.
- Doblin, R. (Autumn 2002). "A Clinical Plan for MDMA (Ecstasy) in the Treatment of Post-traumatic Stress Disorder (PTSD): Partnering with the FDA". MAPS Bulletin 12 (3): 5–18.
- Mithoefer, M.; Jerome, L.; Doblin, R. (2003). "MDMA ('ecstasy') and neurotoxicity". Science 300 (5625): 1504–5.
- Summall, H.; Jerome, L.; Doblin, R. (2004). "Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450". Psychopharmacology 171 (2): 229–30.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Doblin, R. (2010). "The safety and efficacy of 3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study". Journal of Psychopharmacology 25 (4): 439–452. doi:10.1177/0269881110378371.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Martin, S.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T. et al. (2012). "Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study". Journal of Psychopharmacology 27: 28–39.
- Peter, G.; Dominique, H.; Yvonne, M.; R., D.; Berra, Y.-Klosinski; Torsten, P.; Rudolf, B. (2014). "Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases". The Journal of Nervous and Mental Disease 202 (7): 513–20.
- The MAPS Staff
- Erowid character vaults
- Miliard, Mike: This is your brain on drugs: Rick Doblin thinks pot, ecstasy, and other psychedelics could unlock the human mind — and he wants to bring them to Harvard, the FDA, and a doctor’s office near you, The Boston Phoenix, Oct. 8-14, 2004.
- Frood, Arran : Interview: Keeping the psychedelic dream alive, New Scientist Magazine, 27 August 2008 issue 2671
- Cox, Billy (14 August 2008). "Had a nice trip. Wish you could, too.". Herald Tribune. Retrieved 2 November 2012.
- Rick Doblin discusses the current state of research on MDMA (aka 'Ecstacy') and the possible benefits
|This psychedelics, dissociatives and deliriants-related article is a stub. You can help Wikipedia by expanding it.|